VYNE Therapeutics (VYNE) Prepaid Assets (2016 - 2026)
VYNE Therapeutics (VYNE) posted Prepaid Assets of $861000.0 for Q1 2026, down 14.07% on a QoQ basis from $1.0 million in Q4 2025, and down 81.45% year-over-year from $4.6 million in Q1 2025.
VYNE Therapeutics (VYNE) Prepaid Assets (2016 - 2026) Analysis & Trends
VYNE Therapeutics' Prepaid Assets history runs 11 years deep, the most recent figure standing at $861000.0 for Q1 2026.
- Quarterly Prepaid Assets fell 81.45% year-over-year to $861000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $861000.0 (down 81.45% YoY) and the FY2025 annual result came in at $1.0 million, down 65.7% from the prior year.
- Prepaid Assets was $861000.0 for Q1 2026 at VYNE Therapeutics, down from $1.0 million in the prior quarter.
- Across five years, Prepaid Assets topped out at $5.6 million in Q2 2024 and bottomed at $861000.0 in Q1 2026.
- A 5-year average of $3.1 million and a median of $3.0 million in 2022 frame the typical range for Prepaid Assets.
- Annual changes were most pronounced in 2024 — Prepaid Assets soared 178.11% — and 2026, when it sank 81.45%.
- VYNE Therapeutics' Prepaid Assets stood at $2.3 million in 2022, then advanced by 15.48% to $2.7 million in 2023, then gained by 9.98% to $2.9 million in 2024, then sank by 65.7% to $1.0 million in 2025, then retreated by 14.07% to $861000.0 in 2026.
- Business Quant data shows VYNE's Prepaid Assets at $861000.0 in Q1 2026, $1.0 million in Q4 2025, and $4.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | VYNE Therapeutics | 1.19 Bn | 1.16 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 861,000.00 |
| Dec 31, 2025 | 1.00 Mn |
| Jun 30, 2025 | 4.70 Mn |
| Mar 31, 2025 | 4.64 Mn |
| Dec 31, 2024 | 2.92 Mn |
| Sep 30, 2024 | 3.30 Mn |
| Jun 30, 2024 | 5.63 Mn |
| Mar 31, 2024 | 4.22 Mn |
| Dec 31, 2023 | 2.66 Mn |
| Sep 30, 2023 | 1.76 Mn |
| Jun 30, 2023 | 2.02 Mn |
| Mar 31, 2023 | 2.64 Mn |
| Dec 31, 2022 | 2.30 Mn |
| Sep 30, 2022 | 3.00 Mn |
| Jun 30, 2022 | 3.77 Mn |
| Mar 31, 2022 | 3.90 Mn |
| Dec 31, 2021 | 4.57 Mn |
| Sep 30, 2021 | 5.06 Mn |
| Jun 30, 2021 | 5.27 Mn |
| Mar 31, 2021 | 3.87 Mn |